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Abstract
Background: Migraine and tension-type headaches impose a tremendous economic drain upon
the healthcare system. Intravenous and oral niacin has been employed in the treatment of acute
and chronic migraine and tension-type headaches, but its use has not become part of contemporary
medicine, nor have there been randomized controlled trials further assessing this novel treatment.
We aimed to systematically review the evidence of using intravenous and/or oral niacin as a
treatment for migraine headaches, tension-type headaches, and for headaches of other etiologic
types.
Methods: We searched English and non-English language articles in the following databases:
MEDLINE (1966–February 2004), AMED (1995–February 2004) and Alt HealthWatch (1990–
February 2004).
Results:  Nine articles were found to meet the inclusion criteria and were included in this
systematic review. Hypothetical reasons for niacin's effectiveness include its vasodilatory
properties, and its ability to improve mitochondrial energy metabolism. Important side effects of
niacin include flushing, nausea and fainting.
Conclusion: Although niacin's mechanisms of action have not been substantiated from controlled
clinical trials, this agent may have beneficial effects upon migraine and tension-type headaches.
Adequately designed randomized trials are required to determine its clinical implications.
Introduction
Migraines and tension-type headaches impose an impor-
tant burden upon society and the working public. Accord-
ing to the National Headache Foundation, some 45
million Americans suffer from chronic, recurring head-
aches and 28 million of these suffer from migraine head-
aches annually [1]. Furthermore, the work force loses
approximately 50 billion dollars per year due to absentee-
ism and medical expenses caused by headaches, with
more than 157 million workdays lost each year to
migraine sufferers alone [1].
Even though advances have been made with regard to the
treatment of acute migraine headaches (i.e., the triptan
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formulations), many patients often discontinue their
migraine interventions due to treatment dissatisfaction
[2]. Among individuals seeking treatment for tension-type
headaches, the frequency of such headaches is often daily
or almost every day [3]. Unfortunately, chronic tension-
type headaches are associated with analgesic abuse [4],
and are difficult to manage in a primary care setting due
to frequent comorbid psychiatric or analgesic use prob-
lems [5]. Thus, it is imperative that other methods of treat-
ment be researched and developed in order to increase
satisfaction, therapeutic response, and compliance
amongst these patients.
One novel, but not really new treatment option, is the
administration of niacin (nicotinic acid) through intrave-
nous and/or oral routes. Niacin is a well-known over-the-
counter (OTC) supplement primarily used for its ability to
favorably influence cholesterol levels. Recently, there have
been anecdotal reports demonstrating the effectiveness of
niacin for aborting acute migraine attacks [6], and for pre-
venting migraine headaches [7]. To assess the therapeutic
spectrum of niacin's clinical effectiveness, we conducted a
systematic review of the literature to examine the evidence
of intravenous and/or oral niacin as a treatment for
migraine headaches, tension-type headaches, and for
headaches of other etiologic types.
Methods
Literature Search
We conducted a systematic search of English and non-
English language articles in the following databases:
MEDLINE (1966–February 2004), AMED (1995–Febru-
ary 2004) and Alt HealthWatch (1990–February 2004).
Articles were searched with the key search terms
"Migraine" combined with the Boolean Operator "AND
"Niacin" OR "Nicotinic Acid." Additional searches were
conducted with the search terms "Headache" and "Ten-
sion." To supplement the search, we searched through the
references of the articles we found from the databases.
Selection of Articles
To be included in our final review, articles had to report
on the use and administration of niacin for migraine or
any other types of headache. We included articles assess-
ing original reports in both peer-reviewed and non-peer-
reviewed journals.
Quality assessment
We determined the evidence grade of each report found,
based on the hierarchy of evidence developed by the
Oxford Centre for Evidence Based Medicine [8]. Table 1
displays the hierarchy of evidence.
Search Results
A total of 14 articles were screened [6,7,9-20]. Five articles
were excluded in total; three because niacin was not the
sole therapeutic agent used for the treatment of headache
[16], histaminic cephalgia [17], and migraine [20]; and
two because the reports were opinion pieces without any
objective or subjective data to support the assertions made
[13,19]. In total, nine articles were found to meet the
inclusion criteria and were included in this systematic
review [6,7,9-12,14,15,18]. Table 2 displays the character-
istics of the studies included in this review.
Limitations
Article #1 [9]
This case series of 21 patients was limited as it was uncon-
trolled and involved a small number of patients. The
methods that were used to evaluate efficacy of the treat-
ment were primarily based upon a subjective question-
naire or medical record. The results would have been
more meaningful if all the patients used the questionnaire
to evaluate their treatment responses. Finally, although
the symptomatic changes were witnessed immediately
following niacin injection, the lifestyle recommendations
may have had therapeutic benefits as well.
Article #2 [10]
This study involved 100 patients having headaches of
multiple etiologies. This study was not properly control-
led, but did at least provide some comparison against a
group of patients that were not administered the flush
forms of intravenous niacin. The fact that the control
group did not substantially benefit from the intravenous
niacinamide lends more therapeutic efficacy to the ability
of intravenous sodium nicotinate or niacin to have a
marked therapeutic effect. The sample size was sufficient
in number (n = 100), but the determination of therapeu-
tic effectiveness was purely subjective and did not include
any questionnaire or standardized method of evaluation.
Side effects were minimal; 2 patients experienced mild
abdominal cramps, 1 patient vomited but was suspected
as having a pathologic condition of the stomach, and 1
Table 1: Grades of Evidence
A Systematic reviews of randomized controlled trials and/or 
randomized controlled trials.
B Systematic reviews of observational studies and/or high-quality 
observational studies including cohort and case-control 
studies.
C Case-series, case-reports and/or poor quality cohort and case-
control studies.
D Expert opinion without explicit critical appraisal, or based on 
physiology, bench research or "first principles."Nutrition Journal 2005, 4:3 http://www.nutritionj.com/content/4/1/3
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other patient with migraine vomited forty-five minutes
after the injection. A few patients found the treatment to
be worse than their headaches. The authors concluded
that the relief of headaches seemed to be correlated with
the degree of flushing from the sodium nicotinate or
niacin, and that this therapy was most useful among the
migraine, spinal tap, and idiopathic groups.
Article #3 [11]
A number of shortcomings were evident in this article.
The first of which was that the study was not properly con-
trolled and did not contain a placebo group or a group of
patients acting as self-controls. However, some of the
patients were given intravenous treatments on more than
one occasion. This procedure helped in determining treat-
ment reliability and reproducibility since niacin appeared
to achieve therapeutic benefits on several occasions. There
were no standardized methods of evaluating efficacy since
the treatment responses were based upon the medical
record and subjective reports. The results would have been
more meaningful if all the patients used a standardized
questionnaire prior to and after each treatment. In addi-
tion, there was only one male subject and 14 females in
the study.
Article #4 [12]
In this study of 35 patients were given treatments of intra-
venous dihydroergotamine methanesulfonate, intrave-
Table 2: Summary of Articles Demonstrating Niacin's Effectiveness for the Treatment of Migraine Headaches, Tension-type 
Headaches, and Headaches of other Etiologies
Reference Condition n Protocol Outcome Evidence Grade
9 Migraine headaches 21 One initial intramuscular injection 
(IM) followed by a series of 6 or 8 
intravenous (IV) treatments 
(maximum 50 mg), then regular IM 
injections (25–50 mg) combined with 
50–150 mg of oral administration.
17 of the 21 subjects had a positive 
response.
C: case-series
10 Headaches of different 
etiologic types
100 100 mg of IV sodium nicotinate or 
niacin.
75 of the 100 subjects had complete 
relief.
C: case-series
11 Migraine headaches 15 100 mg of IV niacin, and an additional 
50–200 mg if necessary to ensure a 
flushing response of more than 15-
minutes.
13 of the 15 subjects had a positive 
response. The headaches were relieved 
in 27 of the 31 times when niacin was 
administered by IV administration.
C: case-series
12 Tension headaches 35 22 subjects received 100–200 mg of 
IV niacin for a total of 53 times.
13 of the 22 subjects had a positive 
response. The headaches were relieved 
in 41 of the 53 times when niacin was 
administered by IV administration.
C: case-series
14 Emotional or tension 
headaches
5 100 mg of IV niacin regularly for 12 
weeks combined with a graded 
schedule of oral dosing, beginning at 
300 mg daily, increasing to 900 mg 
daily, and tapering down to 300 mg 
daily.
All 5 cases of emotional or tension 
headaches were very responsive to 
both IV and oral niacin.
C: case-series
15 Tension headaches 
accompanied with 
depression
50 100 mg of IV niacin regularly for 23 
weeks and then continued once every 
2 months and as needed. This was 
combined with a graded schedule of 
oral dosing, beginning at 300 mg daily, 
increasing to 900 mg daily, and 
tapering down to 300 mg daily.
In 44 of the 50 subjects the results with 
niacin therapy were very satisfactory 
or favorable.
C: case-series
18 Migraine headaches 1 300–500 mg of niacin were chewed 
and allowed to slightly dissolve in the 
mouth.
Resolution of migraine headaches. C: case-report
6 Migraine Headaches 2 500 mg of oral niacin taken at the 
onset of acute symptoms.
In 2 of the 2 subjects, niacin aborted 
the acute migraine symptoms. In the 
first subject, niacin resolved the acute 
attacks in 4 of 4 occasions. In the other 
subject, niacin resolved the attack on 
one occasion.
C: case-report
7 Migraine headaches 1 375 mg of oral sustained-release 
niacin twice daily for 1 month, and 
375 mg once daily for 2 months.
Migraine-free for the first month, and a 
marked reduction in migraine 
headaches over the next 2 months.
C: Case-reportNutrition Journal 2005, 4:3 http://www.nutritionj.com/content/4/1/3
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nous niacin, or oral combination tablets of ergotamine
tartrate and caffeine. Although no control group was used
in this study, the patients were given multiple treatments
on several occasions. This offered an interesting compari-
son to be made between niacin and other treatments.
Since no control or placebo group was included, it cannot
be determined if the therapeutic results were due, in part,
to chance or placebo effects. The results might have been
more meaningful if all the patients were given a standard-
ized questionnaire prior to and after each treatment, and
if an objective measure was incorporated to further sub-
stantiate patient responses.
Article #5 [14]
These cases reported were well described and clearly dem-
onstrated therapeutic responses during the intravenous
and oral niacin therapy. The results would have been
more reliable if a comparison had been made to a control
group or to a similar patient cohort that were not given the
same treatments. Even if the patients served as self-con-
trols, and were told to stop the niacin treatment for a spec-
ified period of time, more information could have been
gained from their therapeutic responses to niacin. Overall,
this report of five cases provides an interesting approach
to patients having chronic tension headaches and depres-
sion. Its value is limited by the difficulty in extrapolating
these findings to a greater number of patients.
Article #6 [15]
In this study involving 50 patients there was no data that
listed pertinent identifying information, treatment
response, past treatments, and duration of treatment for
each patient. This would have strengthened the report by
being more descriptive, and thus more amenable to criti-
cal analysis. If a comparison were made to a control group
or a similar patient cohort not given the same treatments,
more validity could be have been ascribed to this method
of treatment. The patients could have also served as their
own controls, thus providing more information about the
therapeutic responses to niacin. It cannot be determined
if the therapeutic results were due, in part, to chance or
placebo. No method of evaluating efficacy was men-
tioned, except that the responses to niacin were "very sat-
isfactory" in 44 of 50 cases. The results would have been
more meaningful if all the patients were given a standard-
ized questionnaire prior to and after each treatment, and
if an objective measure was incorporated to substantiate
their responses to niacin.
Article #7 [18]
In this report, Hall describes the use of niacin for his
migraine headaches remarking that the migraines
resolved when intense flushing occurred. According to
Hall, niacin's benefits and side effects might be due to its
ability to release serotonin and histamine from the stom-
ach. There is no reason to doubt Hall when describing his
therapeutic response to niacin. However, his report was
brief, had no control and was entirely subjective as he was
the participant as well as examiner.
Article #8 [6]
In this report of 2 cases, it was found that in both cases
migraines were relieved with oral niacin. The report
would have been more rigorous if the patients had acted
as their own self-controls. The value of the report is further
diminished by the difficulty in extrapolating these find-
ings to a greater number of patients.
Article #9 [7]
This case report was of a 62-year-old woman with a 40-
year history of migraine headaches. The patient never
acted as her own self-control, which would have made the
findings of the case report more meaningful. The fact that
the patient's migraine headaches increased in severity
after a reduction in dosage does lend more support to
niacin as being a migraine preventive agent. The hypothe-
sized increase in serotonin from niacin administration
cannot be proven given the limited amount of data con-
tained in the case report. Like all case reports, its value is
diminished by the difficulty in extrapolating these find-
ings to a greater number of patients.
Discussion
The results of this systematic review indicate that niacin
may have a therapeutic effect on migraine headaches, ten-
sion-type headaches, and headaches of other etiologies.
The quality of the evidence at this point, however, is only
hypothesis generating, and randomized trials are required
to determine the clinical implications of this novel
treatment.
There are several important limitations to consider in the
interpretation of this review. We did not find any rand-
omized or controlled trials of niacin on these headaches.
We cannot determine to what extent publication bias has
on the results of this review. We are unable to draw clini-
cal inferences on the results of the included studies as they
were of low quality and have a low level of external gener-
alizability. Despite these limitations, we attempted to
conduct an exhaustive search and included all reports of
relevance.
Reasons for niacin's effectiveness can only be considered
hypothetical, and require clarification from future rand-
omized controlled trials. In acute migraine headaches
some of the symptoms arise from activation of the
trigeminovascular complex. Activation of this complex
leads to intracranial vasoconstriction causing the
migraine aura, followed by headache due to vasodilation
of the extracranial vessels and activation of the perivascu-Nutrition Journal 2005, 4:3 http://www.nutritionj.com/content/4/1/3
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lar nociceptive nerves [21]. When taken intravenously or
orally, niacin causes cutaneous flushing that might abort
the acute symptoms of migraine by vasodilating the
intracranial vessels, thus preventing the subsequent vaso-
constriction of the extracranial vessels. There is evidence
that niacin is an effective peripheral vasodilator, but its
ability to influence central mechanisms (i.e., cerebral
blood flow and cranial hemodynamics) involved in
migraine headaches have not been well studied. Niacin
causes peripheral vasodilation and cutaneous flushing by
inducing the production of prostaglandin D2 (PGD2) in
the skin, leading to a marked increase of its metabolite,
9α, 11β-PGF2, in the plasma [22]. When niacin is admin-
istered orally in amounts of 500 mg or topically via a 6-
inch patch of 10-1 M aqueous methylnicotinate on the
forearm, PGD2 is markedly released in the skin and its
metabolite appears in high amounts in the plasma
[22,23]. It is not known if PGD2 causes vasodilation of the
intracranial arteries, but niacin's ability to abort acute
migraine headaches suggests that this might be what is
occurring. Old reports cited by Bicknell and Prescott [24],
demonstrate that niacin does indeed cause vasodilation of
the cerebral and spinal vessels, and that intravenous
administration increases the rate of intracranial blood
flow in human beings for 20–60 minutes without any sig-
nificant change in blood pressure. Unfortunately, there
have not been more recent reports examining the effects
that niacin has upon cerebral blood flow in human
subjects.
In terms of tension-type headaches, it appears that intra-
venous niacin is of benefit acutely due to its presumed
central vasodilatory properties. Like migraines, part of the
underlying pathophysiology of chronic tension-type
headaches involves central mechanisms, such as the
trigeminal system [26]. Chronic tension-type headaches
are also associated with cerebrospinal pressure or intracra-
nial venous pressure (or both) [26]. In fact, tension-type
headaches are more similar to migraine headaches than
they are dissimilar, in that they seem to progress into
migraine headaches due to an escalating pathophysiolog-
ical process [27]. Thus, niacin might mitigate the acute
phase of tension-type headaches through the same
hypothesized mechanism of action described earlier.
Some of the reports did demonstrate prophylactic benefits
when niacin was administered orally every day. It is now
recognized that a deficit of mitochondrial energy metabo-
lism (i.e., impaired mitochondrial phosphorylation
potential) plays a role in the pathogenesis of chronic
migraine headaches [28]. Niacin maintains adequate
mitochondrial energy metabolism by increasing substrate
availability to complex I [29], and this is how it might
function as an effective prophylactic agent for migraine
prevention. Two other nutritional agents (riboflavin and
coenzyme Q10) augment complex I of the mitochondrial
respiratory chain, and have been subjected to clinical tri-
als demonstrating their effectiveness for the prevention of
migraine headaches [30-32]. A deficit of mitochondrial
energy metabolism may play a role in the pathogenesis of
migraine. Since niacin improves mitochondrial energy
metabolism by increasing substrate availability to com-
plex I, it might also be an effective agent for migraine
prevention.
Niacin might also prevent tension-type headaches by
improving mitochondrial energy metabolism within the
skeletal muscles, and by increasing blood flow and oxy-
genation to the skeletal muscles. The overall net-effect
could be a reduction in lactic acid concentrations, leading
to reduced episodes of muscular tension and soreness.
Niacin may reduce lactic acid concentrations since supple-
mental niacinamide (the amide of niacin) has been
shown to reduce blood lactate and pyruvate concentra-
tions by more than 50% in a patient with MELAS (mito-
chondrial encephalopathy, myopathy, lactic acidosis, and
stroke-like episodes) syndrome by the third day of treat-
ment [33]. This possible mechanism might only relate to
migraine sufferers, however, since plasma levels of lactic
and pyruvic acids were found to be significantly higher in
migraine patients compared to patients with tension-type
headaches and normal controls [34].
The side effects of intravenous niacin were found to be
minimal from the summarized articles. The most com-
mon side effects were abdominal cramping, vomiting,
and uncomfortable sensations of the skin and burning. A
few of the patients described found the treatments to be
worse than their headaches. In the articles where blood
pressures were evaluated, little-to-no change occurred
among the individuals treated with intravenous niacin. In
a more recent study, parenteral niacin given to hyperten-
sive and normotensive patients demonstrated a signifi-
cant decrease in systolic, diastolic, and pulse pressures
among the hypertensive subjects [35].
With respect to the oral administration of niacin, very few
patients reported side effects. Even though niacin was well
tolerated orally, we previously reported in a randomized
placebo-controlled trial examining the safety of immedi-
ate-release or crystalline niacin, that it can be associated
with intolerable side effects [36]. The most common side
effects found using 500 mg of immediate-release niacin
were unpleasant warmth or flushing, pruritis, chills, tin-
gling, nausea, and vomiting. Approximately 75% of the
subjects who were given niacin found it tolerable or diffi-
cult to tolerate, but did not indicate that they would never
take niacin again. Some 18.2% of the niacin subjects indi-
cated that they found niacin to be intolerable and would
never take it again [36]. By contrast, very few of theNutrition Journal 2005, 4:3 http://www.nutritionj.com/content/4/1/3
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patients from the summarized articles discontinued treat-
ment due to the side effects of oral niacin.
The side effects of greater concern from oral niacin have to
do with sustained- or slow-release preparations. These
preparations are better in terms of compliance since
patients experience less cutaneous flushing with them.
However, the use of these preparations have been associ-
ated with reversible hepatic toxicity in doses equal to or
greater than 1500 mg per day with an acute onset of clin-
ical symptoms of hepatitis in a relatively short period of
time (2 days to 7 weeks) [37]. Other reports have demon-
strated clinical symptoms of hepatitis when much larger
doses of sustained-release niacin (greater than or equal to
3 grams per day) were used for months to years [38-42].
Sustained-release preparations have a higher incidence of
hepatic toxicity in doses comparable to the immediate-
release preparations [43], but these important differences
are not typically mentioned in reviews of niacin's lipid
lowering properties.
Conclusion
Even though niacin's mechanisms of action have not been
substantiated from controlled clinical trials. It is possible
that this agent has a beneficial effect upon migraine and
tension-type headaches and the prophylaxis of these
headaches. It is imperative that properly designed control-
led trials are developed in order to determine niacin's true
therapeutic effects and adverse effect profile. In terms of
its ability to abort acute migraine headaches, a placebo-
controlled trial of parenteral niacin and sumatriptan
seems to be worthy of consideration. In terms of prophy-
laxis, a placebo-controlled trial of oral niacin and ribofla-
vin or coenzyme Q10 also seems worthy of investigation.
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